Solid lipid nanoparticles for targeted natural and synthetic drugs delivery in high-incidence cancers, and other diseases: Roles of preparation methods, lipid composition, transitional stability, and release profiles in nanocarriers’ development
Source abstract
Abstract
Abstract Solid lipid nanoparticles (SLNs), the spheroidal-shaped, colloids state lipophilic-natured, innovative nanoscale particulate materials, are being concurrently prepared by the quality-by-design approach for cellular and sub-cellular delivery of drugs and other payloads with facilitated physicochemical characteristics for targeted delivery. The delivery of drugs, other pharmaceuticals and biopharmaceutical materials, and genes to the diseased body organs, tissues, and cellular mass have been developed as promising nanocarriers for different high-incidence cancers and other disease therapies, including the Alzheimer’s, Parkinson’s, and tuberculosis. SLNs have evolved as favorable lipid-based formulation, and have served as oral and intravenous carriers that targeted the drug with stable and sterile transport, sustained delivery, controlled drug/payload deloading, and requisite biodistributions. SLNs advantages, shortcomings, and bottlenecks have been discussed with plausible remediation strategies. The laboratory-scale and bulk preparations, use of different lipids in various preparation, surface coatings, physicochemical properties of the final product, and characterization protocols are also encompassed, as are the routes of administrations, specific-sites-targeting, and on-site outreach with biocompatibility, bioavailability, and the absorption, distribution, metabolism, and excretion and pharmacokinetics, and pharmacodynamics inputs with relevance to the therapy. Plausible applications in complex and genetic disorders, and as personalized medicine, also of traditional and alternative medicine prospects, are also discussed.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Advancements in Transdermal Drug Delivery · Lipid Membrane Structure and Behavior · Essential Oils and Antimicrobial Activity
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Qassim University , Qassim 51452 , Saudi Arabia
Department of Pharmacognosy and Medicinal Plants, Faculty of Pharmacy, Al-Azhar University , Cairo , Egypt
Department of Biomedical Engineering, MRIU-MRIRS , Faridabad , HR 121 001 , India
Department of Clinical Pharmacy, College of Pharmacy, Taif University , P.O. Box 11099 , Taif 21944 , Saudi Arabia
Department of Pharmaceutics, College of Dentistry and Pharmacy, Buraydah Private Colleges , Buraydah , 51418 , Saudi Arabia
Division of Biotechnology, Department of Applied Sciences, University of Technology , Baghdad , 10066 , Iraq
Department of Chemistry, College of Sciences, University of Misan , Maysan , 62001 , Iraq
Department of Pharmaceutics, College of Pharmacy, Qassim University , Qassim , 51452 , Saudi Arabia
Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Al-Azhar University , Assiut , 71524 , Egypt
Department of Pharmacognosy and Phytochemistry, RV Northland Institute, Greater NOIDA-II , Gautam Budh Nagar , UP , India
Deprtment of Pharmacology and Toxicology, College of Pharmacy, Qassim University , Qassim 51452 , Saudi Arabia
References (100+)
Show source-provided references
1. Mukherjee S, Ray S, Thakur R. Solid lipid nanoparticles: A modern formulation approach in the drug delivery system. Indian J Pharm Sci. 2009;71(4):349–58. 10.4103/0250-474X.57282.10.4103/0250-474X.57282 ↗
2. Choonara YE, Pillay V, Ndesendo VM, du Toit LC, Kumar P, Khan RA, et al. Polymeric emulsion and crosslink-mediated synthesis of super-stable nanoparticles as sustained-release anti-tuberculosis drug carriers. Colloids Surf B Biointerfaces. 2011;87(2):243–54. 10.1016/j.colsurfb.2011.05.025.10.1016/j.colsurfb.2011.05.025 ↗
3. Akhtar N, Khan RA. Liposomal systems as viable drug delivery technology for skin cancer sites with an outlook on lipid-based delivery vehicles and diagnostic imaging inputs for skin conditions. Prog lipid Res. 2016;64:192–230. 10.1016/j.colsurfb.2011.05.025.10.1016/j.plipres.2016.08.005 ↗
4. Akhtar N, Mohammed SA, Khan RA, Yusuf M, Singh V, Mohammed HA, et al. Self-generating nano-emulsification techniques for alternatively routed, bioavailability enhanced delivery, especially for anti-cancers, anti-diabetics, and miscellaneous drugs of natural, and synthetic origins. J Drug Delivery Sci Technol. 2020;58:101808. 10.1016/j.jddst.2020.101808.10.1016/j.jddst.2020.101808 ↗
5. Yusuf M, Khan M, Khan RA, Maghrabi IA, Ahmed B. Polysorbate-80-coated, polymeric curcumin nanoparticles for in vivo anti-depressant activity across BBB and envisaged biomolecular mechanism of action through a proposed pharmacophore model. J Microencapsul. 2016;33(7):646–55. 10.1080/02652048.2016.1242666.10.1080/02652048.2016.1242666 ↗
6. Khateef R, Khadri H, Almatroudi A, Alsuhaibani SA, Mobeen SA, Khan RA. Potential in-vitro anti-breast cancer activity of green-synthesized silver nanoparticles preparation against human MCF-7 cell-lines. Adv Nat Sci Nanosci Nanotechnol. 2019;10:045012. 10.1088/2043-6254/ab47ff.10.1088/2043-6254/ab47ff ↗
7. Akhtar N, Mohammed HA, Yusuf M, Al-Subaiyel A, Sulaiman GM, Khan RA. SPIONs Conjugate Supported Anticancer Drug Doxorubicin’s Delivery: Current Status, Challenges, and Prospects. Nanomaterials. 2020;12(20):3686. 10.3390/nano12203686.10.3390/nano12203686 ↗
8. Sibeko B, Choonara YE, du Toit LC, Modi G, Naidoo D, Khan RA, et al. Composite polylactic-methacrylic acid copolymer nanoparticles for the delivery of methotrexate. J drug delivery. 2012;2012:579629. 10.1155/2012/579629.10.1155/2012/579629 ↗
9. Qureshi KA, Mohammed SA, Khan O, Ali HM, El-Readi MZ, Mohammed HA. Cinnamaldehyde-Based Self-Nanoemulsion (CA-SNEDDS) Accelerates Wound Healing and Exerts Antimicrobial, Antioxidant, and Anti-Inflammatory Effects in Rats’ Skin Burn Model. Molecules. 2022;27(16):5225. 10.3390/molecules27165225.10.3390/molecules27165225 ↗
10. Jumaa M, Muller BW. Lipid emulsions as a novel system to reduce the hemolytic activity of lytic agents: Mechanism of protective effect. Eur J Pharm Sci. 2000;9:285–90. 10.1016/s0928-0987(99)00071-8.10.1016/S0928-0987(99)00071-8 ↗
11. Cavalli R, Caputo O, Gasco MR. Solid lipospheres of doxorubicin and idarubicin. Int J Pharm. 1993;89:R9–12. 10.1016/S0928-0987(99)00071-8.10.1016/0378-5173(93)90313-5 ↗
12. Scheffel U, Rhodes BA, Natarajan TK, Wagner HN. Albumin microspheres for study of the reticuloendothelial system. J Nuc Med. 1972;13(7):498–503.
13. Sabapati M, Palei NN, Ashok AK, Molakpogu RB. Solid lipid nanoparticles of Annona muricata fruit extract: formulation, optimization and in vitro cytotoxicity studies. Drug Dev Ind Pharm. 2019;45(4):577–86. 10.1080/03639045.2019.1569027.10.1080/03639045.2019.1569027 ↗
14. Nooli M, Chella N, Kulhari H, Shastri NR, Sistla R. Solid lipid nanoparticles as vesicles for oral delivery of olmesartan medoxomil: formulation, optimization and in vivo evaluation. Drug Dev Ind Pharm. 2017;43(4):611–7. 10.1080/03639045.2016.1275666.10.1080/03639045.2016.1275666 ↗
15. Gasco MR. Method for producing solid lipid microspheres having a narrow size distribution. United States patent, US 188837; 1993.
16. Muller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Delivery Rev. 2002;54:131–55. 10.1016/S0169-409X(02)00118-7.10.1016/S0169-409X(02)00118-7 ↗
17. Saez V, de Souza IDL, Mansur CRE. Lipid nanoparticles (SLN & NLC) for delivery of vitamin E: A comprehensive review. Int J Cosmetic Sci. 2018;40(2):103–16. 10.1111/ics.12452.10.1111/ics.12452 ↗
18. Kalaycioglu GD, Aydogan N. Preparation and investigation of solid lipid nanoparticles for drug delivery. Colloids Surf A Physicochem Eng Asp. 2016;510:77–86. 10.1016/j.colsurfa.2016.06.034.10.1016/j.colsurfa.2016.06.034 ↗
19. Khurana S, Bedi PMS, Jain NK. Preparation and evaluation of solid lipid nanoparticles based nanogel for dermal delivery of meloxicam. Chem Phys Lipids. 2013;175:65–72. 10.1016/j.chemphyslip.2013.07.010.10.1016/j.chemphyslip.2013.07.010 ↗
20. Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization, and application. Adv Drug Del Rev. 2001;47(2–3):165–96. 10.1016/s0169-409x(01)00105-3.10.1016/S0169-409X(01)00105-3 ↗
21. Manjunath K, Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Rel. 2005;107(2):215–28. 10.1016/j.jconrel.2005.06.006.10.1016/j.jconrel.2005.06.006 ↗
22. Ebrahimi HA, Javadzadeh Y, Hamidi M, Jalali MB. Repaglinide-loaded solid lipid nanoparticles: effect of using different surfactants/stabilizers on the physicochemical properties of nanoparticles. DARU J Pharma Sci. 2015;23(1):46. 10.1186/s40199-015-0128-3.10.1186/s40199-015-0128-3 ↗
23. Pizzol CD, Filippin-Monteiro FB, Restrepo JA, Pittella F, Silva AH, Alves de Souza P, et al. Influence of surfactant and lipid type on the physicochemical properties and biocompatibility of solid lipid nanoparticles. Inter J Env Res Pub Health. 2014;11(8):8581–96. 10.3390/ijerph110808581.10.3390/ijerph110808581 ↗
24. Silva AC, Kumar A, Wild W, Ferreira D, Santos D, Forbes B. Long-term stability, biocompatibility, and oral delivery potential of risperidone-loaded solid lipid nanoparticles. Inter J Pharm. 2012;436(1):798–805. 10.1016/j.ijpharm.2012.07.058.10.1016/j.ijpharm.2012.07.058 ↗
25. Göppert TM, Müller RH. Adsorption kinetics of plasma proteins on solid lipid nanoparticles for drug targeting. Inter J Pharm. 2005;302(1):172–86. 10.1016/j.ijpharm.2005.06.025.10.1016/j.ijpharm.2005.06.025 ↗
26. Mueller RH, Maeder K, Gohla S. Solid lipid nanoparticles (SLNs) for controlled drug delivery–a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161–77. 10.1016/s0939-6411(00)00087-4.10.1016/S0939-6411(00)00087-4 ↗
27. Müller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm. 2002;242(1–2):121–8. 10.1016/s0378-5173(02)00180-1.10.1016/S0378-5173(02)00180-1 ↗
28. Muller RH, Runge SA. Solid lipid nanoparticles (SLN) for controlled drug delivery. In: Benita S, editor. Submicron emulsions in drug targeting and delivery. Amsterdam: Harwood Academic Publishers; 1998. p. 219–34.10.1201/9780367810528-9 ↗
29. Jenning V, Gysler A, Schafer-Korting M, Gohla S. Vitamin A loaded solid lipid nanoparticles for topical use: Occlusive properties and drug targeting to the upper skin. Eur J Pharm Biopharm. 2000;49:211–8.10.1016/S0939-6411(99)00075-2 ↗
30. Mohammadi P, Mahjub R, Mohammadi M, Derakhshandeh K, Ghaleiha A, Mahboobian MM. Pharmacokinetics and brain distribution studies of perphenazine-loaded solid lipid nanoparticles. Drug Dev Ind Pharm. 2021;47:146–52. 10.1080/03639045.2020.1862172.10.1080/03639045.2020.1862172 ↗
31. Almeida AJ, Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Delivery Rev. 2007;59(6):478–90. 10.1016/j.addr.2007.04.007.10.1016/j.addr.2007.04.007 ↗
32. Satapathy MK, Yen TL, Jan JS, Tang RD, Wang JY, Taliyan R, et al. Solid lipid nanoparticles (SLNs): an advanced drug delivery system targeting brain through BBB. Pharmaceutics. 2021;13(8):1183. 10.3390/pharmaceutics13081183.10.3390/pharmaceutics13081183 ↗
33. Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MDP, Acosta-Torres LS, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnol. 2018;16(1):1–33. 10.1186/s12951-018-0392-8.10.1186/s12951-018-0392-8 ↗
34. Muller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of the drug. Int J Pharm. 2002;242:121–8.10.1016/S0378-5173(02)00180-1 ↗
35. Radtke M, Muller RH. Comparison of structural properties of solid lipid nanoparticles (SLN) versus other lipid particles. Proc Int Symp Control Rel Bioact Mater. 2000;27:309–10.
36. Uner M. Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): Their benefits as colloidal drug carrier systems. Pharmazie. 2006;61:375–86.
37. Souto EB, Wissing SA, Barbosa CM, Muller RH. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm. 2004;278:71–7.10.1016/j.ijpharm.2004.02.032 ↗
38. Souto EB, Muller RH. Investigation of the factors influencing the incorporation of clotrimazole in SLN and NLC prepared by hot high-pressure homogenization. J Microencap. 2006;23:377–88.10.1080/02652040500435295 ↗
39. Souto EB, Muller RH. SLN and NLC for topical delivery of ketoconazole. J Microencap. 2005;22:501–10.10.1080/02652040500162436 ↗
40. Souto EB, Muller RH. The use of SLN and NLC as topical particulate carriers for imidazole antifungal agents. Pharmazie. 2006;61:431–37.
41. Morel S, Terreno E, Ugazio E, Aime S, Gasco MR. NMR relaxometric investigations of lipid nanoparticles (SLN) containing gadolinium (III) complexes. Eur J Pharm Biopharm. 1998;45:157–63.10.1016/S0939-6411(97)00107-0 ↗
42. Olbrich C, Gebner A, Kayser O, Muller RHL. Lipid–drug conjugate (LDC) nanoparticles as a novel carrier system for the hydrophilic anti-trypanosomal drug diminazene diaceturate. J Drug Target. 2002;10:387–96.10.1080/1061186021000001832 ↗
43. Shah RM, Rajasekaran D, Ludford-Menting M, Eldridge DS, Palombo EA, Harding IH. Transport of stearic acid-based solid lipid nanoparticles (SLNs) into human epithelial cells. Colloids Surf B: Biointerfaces. 2016;140:204–12. 10.1016/j.colsurfb.2015.12.029.10.1016/j.colsurfb.2015.12.029 ↗
44. Lim SB, Banerjee A, Önyüksel H. Improvement of drug safety by the use of lipid-based nanocarriers. J Control Rel. 2012;163(1):34–45. 10.1016/j.jconrel.2012.06.002.10.1016/j.jconrel.2012.06.002 ↗
45. Gastaldi L, Battaglia L, Peira E, Chirio D, Muntoni E, Solazzi I, et al. Solid lipid nanoparticles as vehicles of drugs to the brain: current state of the art. Eur J Pharm Biopharm. 2014;87(3):433–44. 10.1016/j.ejpb.2014.05.004.10.1016/j.ejpb.2014.05.004 ↗
46. Makwana V, Jain R, Patel K, Nivsarkar M, Joshi A. Solid lipid nanoparticles (SLN) of Efavirenz as lymph targeting drug delivery system: Elucidation of mechanism of uptake using chylomicron flow blocking approach. Int J Pharmaceutics. 2015;495(1):439–46. 10.1016/j.ijpharm.2015.09.014.10.1016/j.ijpharm.2015.09.014 ↗
47. Alex MA, Chacko AJ, Jose S, Souto EB. Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting. Eur J Pharm Sci. 2011;42(1–2):11–8. 10.1016/j.ejps.2010.10.002.10.1016/j.ejps.2010.10.002 ↗
48. Chen H, Chang X, Du D, Liu W, Liu J, Weng T, et al. Podophyllotoxin-loaded solid lipid nanoparticles for epidermal targeting. J Controlled Rel. 2006;110(2):296–306. 10.1016/j.jconrel.2005.09.052.10.1016/j.jconrel.2005.09.052 ↗
49. Liu J, Hu W, Chen H, Ni Q, Xu H, Yang X. Isotretinoin-loaded solid lipid nanoparticles with skin targeting for topical delivery. Int J Pharm. 2007;328:191–5. 10.1016/j.ijpharm.2006.08.007.10.1016/j.ijpharm.2006.08.007 ↗
50. Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Pineros M, Znaor A, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021;149:778–89. 10.1002/ijc.33588.10.1002/ijc.33588 ↗
51. Malik Z, Parveen R, Abass S, Dar MI, Husain SA, Ahmad S. Receptor-mediated targeting in breast cancer through solid lipid nanoparticles and its mechanism. Curr Drug Metab. 2022;23(10):800–17. 10.2174/1389200223666220416213639.10.2174/1389200223666220416213639 ↗
52. Martins S, Costa-Lima S, Carneiro T, Cordeiro-daSilva A, Souto EB, Ferreira DC. Solid lipid nanoparticles as intracellular drug transporters: an investigation of the uptake mechanism and pathway. Int J Pharm. 2012;430(1–2):216–27. 10.1016/j.ijpharm.2012.03.032.10.1016/j.ijpharm.2012.03.032 ↗
53. Singh I, Swami R, Pooja D, Jeengar MK, Khan W, Sistla R. Lactoferrin bioconjugated solid lipid nanoparticles: a new drug delivery system for potential brain targeting. J drug tar-geting. 2016;24(3):212–23. 10.3109/1061186X.2015.1068320.10.3109/1061186X.2015.1068320 ↗
54. Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW, Yang CZ. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Rel. 1999;59:299–307. 10.1016/S0168-3659(99)00007-3.10.1016/S0168-3659(99)00007-3 ↗
55. Martins SM, Sarmento B, Nunes C, Lúcio M, Reis S, Ferreira DC. Brain targeting effect of camptothecin-loaded solid lipid nanoparticles in rat after intravenous administration. Eur J Pharm Biopharm. 2013;85:488–502. 10.1016/j.ejpb.2013.08.011.10.1016/j.ejpb.2013.08.011 ↗
56. Parvez S, Kaushik M, Ali M, Alam MM, Ali J, Tabassum H, et al. Dodging blood brain barrier with “nano” warriors: Novel strategy against ischemic stroke. Theranostics. 2022;12(2):689–719. 10.7150/thno.64806.10.7150/thno.64806 ↗
57. Dal Magro R, Ornaghi F, Cambianica I, Beretta S, Re F, Musicanti C, et al. ApoE-modified solid lipid nanoparticles: A feasible strategy to cross the blood-brain barrier. J Controlled Rel. 2017;249:103–10. 10.1016/j.jconrel.2017.01.039.10.1016/j.jconrel.2017.01.039 ↗
58. Ghasemiyeh P, Mohammadi-Samani S. Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: Applications, advantages and disadvantages. Res Pharm Sci. 2018;13(4):288–303. 10.4103/1735-5362.235156.10.4103/1735-5362.235156 ↗
59. Garcês A, Amaral MH, Lobo JS, Silva AC. Formulations based on solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for cutaneous use: A review. Eur J Pharm Sci. 2018;112:159–67. 10.1016/j.ejps.2017.11.023.10.1016/j.ejps.2017.11.023 ↗
60. Wissing SA, Kayser O, Muller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev. 2004;56:1257–72. 10.1016/j.addr.2003.12.002.10.1016/j.addr.2003.12.002 ↗
61. Patel MH, Mundada VP, Sawant KK. Fabrication of solid lipid nanoparticles of lurasidone HCl for oral delivery: Optimization, in vitro characterization, cell line studies and in vivo efficacy in schizophrenia. Drug Dev Ind Pharm. 2019;45(8):1242–57. 10.1080/03639045.2019.1593434.10.1080/03639045.2019.1593434 ↗
62. Domb AJ. Lipospheres for controlled delivery of substances. United States Patent, US 188837; 1993.
63. Ahlin P, Kristl J, Kobar S. Optimization of procedure parameters and physical stability of solid lipid nanoparticles in dispersion. Acta Pharm. 1998;48:257–67.
64. Cavalli R, Marengo E, Rodriguez L, Gasco MR. Effects of some experimental factors on the production process of solid lipid nanoparticles. Eur J Pharm Biopharm. 1996;43:110–15.
65. Jahnke S. The theory of high-pressure homogenization. In: Muller RH, Benita S, Bohm B, editors. Emulsions and nanosuspensions for the formulation of poorly soluble drugs. Stuttgart: Medpharm Scientific Publishers; 1998. p. 177–200.
66. Mullen zur A. Feste Lipid-Nanopartikel mit prolongierter Wirkstoffliberation: Herstellung, Langzeitstabilitat, Charakterisierung, Freisetzungsverhalten und mechanismen. PhD thesis. Germany: Free University of Berlin; 1996.
67. Sjostrom B, Bergenstahl B. Preparation of submicron drug particles in lecithin-stabilized o/w emulsions: I: Model studies of the precipitation of cholesteryl acetate. Int J Pharm. 1992;88:53–62.10.1016/0378-5173(92)90303-J ↗
68. Jenning V, Lippacher A, Gohla SH. Medium-scale production of solid lipid nanoparticles (SLNs) by high-pressure homogenization. J Microencap. 2002;19(1):1–10.10.1080/713817583 ↗
69. Cavalli R, Caputo O, Marengo E, Pattarino F, Gasco M. The effect of the components of microemulsions on both size and crystalline structure of solid lipid nanoparticles containing the series of model molecules. Pharmazie. 1998;53(6):392–96.
70. Khairnar SV, Pagare P, Thakre A, Nambiar AR, Junnuthula V, Abraham MC, et al. Review on the scale-up methods for the preparation of solid lipid nanoparticles. Pharmaceutics. 2022;14:1886. 10.3390/pharmaceutics14091886.10.3390/pharmaceutics14091886 ↗
71. Albukhaty S, Al-Musawi S, Abdul Mahdi S, Sulaiman GM, Alwahibi MS, Dewir YH, et al. Investigation of dextran-coated superparamagnetic nanoparticles for targeted vinblastine controlled release, delivery, apoptosis induction, and gene expression in pancreatic cancer cells. Molecules. 2020;25(20):4721. 10.3390/molecules25204721.10.3390/molecules25204721 ↗
72. Schwarz C, Mehnert W, Lucks JS, Müller RH. Solid lipid nanoparticles (SLNs) for controlled drug delivery. I. Production, characterization, and sterilization. J Control Rel. 1994;30(1):83–96.10.1016/0168-3659(94)90047-7 ↗
73. Lander R, Manger W, Scouloudis M, Ku A, Davis C, Lee A. Gaulin homogenization: A mechanistic study. Biotech Prog. 2000;16(1):80–5.10.1021/bp990135c ↗
74. Kasongo KW, Muller RH, Walker RB. The use of hot and cold high pressure homogenization to enhance the loading capacity and encapsulation efficiency of nanostructured lipid carriers for the hydrophilic antiretroviral drug, didanosine for potential administration to paediatric patients. Pharm Dev Technol. 2012;17(3):353–62. 10.3109/10837450.2010.542163.10.3109/10837450.2010.542163 ↗
75. Subroto E, Andoyo R, Indiarto R, Wulandari E, Wadhiah EFN. Preparation of solid Lipid nanoparticle-ferrous sulfate by double emulsion method based on fat rich in monolaurin and stearic acid. Nanomaterials. 2022;12(17):3054. 10.3390/nano12173054.10.3390/nano12173054 ↗
76. Sjöström B, Kaplun A, Talmon Y, Cabane B. Structures of nanoparticles prepared from oil-in-water emulsions. Pharma Res. 1995;12(1):39–48.10.1023/A:1016278302046 ↗
77. Shahgaldian P, Da Silva E, Coleman AW, Rather B, Zaworotko MJ. Para-acyl-calixarene-based solid lipid nanoparticles (SLNs): a detailed study of preparation and stability parameters. Inter J Pharma. 2003;253(1):23–38.10.1016/S0378-5173(02)00639-7 ↗
78. Satari N, Taymouri S, Varshosaz J, Rostami M, Mirian M. Preparation and evaluation of inhalable dry powder containing glucosamine-conjugated gefitinib SLNs for lung cancer therapy. Drug Dev Ind Pharm. 2020;46(8):1265–77. 10.1080/03639045.2020.1788063.10.1080/03639045.2020.1788063 ↗
79. Yousry C, Fahmy RH, Essam T, El-Laithy HM, Elkheshen SA. Nanoparticles as tool for enhanced ophthalmic delivery of vancomycin: a multidistrict-based microbiological study, solid lipid nanoparticles formulation and evaluation. Drug Dev Ind Pharm. 2016;42(11):1752–62. 10.3109/03639045.2016.1171335.10.3109/03639045.2016.1171335 ↗
80. Eltom SEM, Abdellatif AAH, Maswadeh H, Al-Omar MS, Abdel-Hafez AA, Mohammed HA, et al. The anti-inflammatory effect of a γ-lactone isolated from ostrich oil of Struthio camelus (Ratite) and its formulated nano-emulsion in formalin-induced paw edema. Molecules. 2021;26(12):3701. 10.3390/molecules26123701.10.3390/molecules26123701 ↗
81. Schubert MA, Müller-Goymann CC. Solvent injection as a new approach for manufacturing lipid nanoparticles-evaluation of the method and process parameters. Eur J Pharm Biopharm. 2003;55(1):125–31.10.1016/S0939-6411(02)00130-3 ↗
82. Yang R, Gao R, Li F, He H, Tang X. The influence of lipid characteristics on the formation, in vitro release, and in vivo absorption of protein-loaded SLN prepared by the double emulsion process. Drug Dev Ind Pharm. 2011;37(2):139–48. 10.3109/03639045.2010.497151.10.3109/03639045.2010.497151 ↗
83. Hillert M. A solid-solution model for inhomogeneous systems. Acta metallurgica. 1961;9(6):525–35. 10.1016/0001-6160(61)90155-9.10.1016/0001-6160(61)90155-9 ↗
84. Zur Muhlen A, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur J Pharm Biopharm. 1998;45(2):149–55. 10.1016/s0939-6411(97)00150-1.10.1016/S0939-6411(97)00150-1 ↗
85. Domb A. Long-acting injectable oxytetracycline-liposphere formulations. Inter J Pharm. 1995;124(2):271–8.10.1016/0378-5173(95)00098-4 ↗
86. Esposito E, Fantin M, Marti M, Drechsler M, Paccamiccio L, Mariani P. Solid lipid nanoparticles as delivery systems for bromocriptine. Pharma Res. 2008;25(7):1521–30.10.1007/s11095-007-9514-y ↗
87. Naguib Y, Rodriguez B, Li X, Hursting S, Williams R, Cui Z. Solid lipid nanoparticle formulations of docetaxel prepared with high melting point triglycerides: In vitro and in vivo evaluations. Mol Pharm. 2014;11(4):1239–49.10.1021/mp4006968 ↗
88. Mokhtar N, Khan N, Darwis Y. Solid lipid nanoparticles of atovaquone based on 24 full-factorial design. Iran J Pharm Res. 2015;14(4):989–1000.
89. Xu W, Lim S, Lee M. Cellular uptake and antitumor activity of paclitaxel incorporated into trilaurin-based solid lipid nanoparticles in ovarian cancer. J Microencapsul. 2013;30(8):755–61. 10.3109/02652048.2013.10.3109/02652048.2013.788083 ↗
90. Manjunath K, Venkateswarlu V, Hussain A. Preparation and characterization of nitrendipine solid lipid nanoparticles. Pharmazie. 2011;66:178–86.
91. Martins S, Silva A, Ferreira D, Souto E. Improving oral absorption of salmon calcitonin by trimyristin lipid nanoparticles. J Biomed Nanotech. 2009;5(1):76–83.10.1166/jbn.2009.443 ↗
92. Patel M, San Martin-Gonzalez M. Characterization of ergocalciferol loaded solid lipid nanoparticles. J Food Sci. 2012;77(1):N8–13.10.1111/j.1750-3841.2011.02517.x ↗
93. Puglia C, Offerta A, Tirendi G, Tarico M, Curreri S, Bonina F. Design of solid lipid nanoparticles for caffeine topical administration. Drug Del. 2014;23(1):36–40.10.3109/10717544.2014.903011 ↗
94. Tran TH, Ramasamy T, Truong DH, Shin BS, Choi HG, Yong CS, et al. Development of vorinostat-loaded solid lipid nanoparticles to enhance pharmacokinetics and efficacy against multidrug-resistant cancer cells. Pharm Res. 2014;31:1978–88. 10.1007/s11095-014-1300-z.10.1007/s11095-014-1300-z ↗
95. Abdelbary G, Fahmy RH. Diazepam-loaded solid lipid nanoparticles: design and characterization. AAPS PharmSciTech. 2009;10(1):211–9. 10.1208/s12249-009-9197-2.10.1208/s12249-009-9197-2 ↗
96. Madureira AR, Nunes S, Campos DA, Fernandes JC, Marques C, Zuzarte M, et al. Safety profile of solid lipid nanoparticles loaded with rosmarinic acid for oral use: in vitro and animal approaches. Int J Nanomed. 2016;11:3621–40. 10.2147/IJN.S104623.10.2147/IJN.S104623 ↗
97. Campos D, Madureira A, Gomes A, Sarmento B, Pintado M. Optimization of the production of solid Witepsol nanoparticles loaded with rosmarinic acid. Colloids Surf B Biointerfaces. 2014;115:109–17.10.1016/j.colsurfb.2013.10.035 ↗
98. Sütő B, Berkó S, Kozma G, Kukovecz Á, Budai-Szűcs M, Erős G, et al. Development of ibuprofen-loaded nanostructured lipid carrier-based gels: characterization and investigation of in vitro and in vivo penetration through the skin. Int J Nanomed. 2016;11:1201–12. 10.2147/IJN.S99198.10.2147/IJN.S99198 ↗
99. Monteiro LM, Löbenberg R, Cotrim PC, Barros de Araujo GL, Bou-Chacra N. Buparvaquone nanostructured lipid carrier: Development of an affordable delivery system for the treatment of leishmaniases. Biomed Res Int. 2017;2017:9781603. 10.1155/2017/9781603.10.1155/2017/9781603 ↗
100. Shenoy VS, Gude RP, Murthy RSR. In vitro anticancer evaluation of 5-fluorouracil lipid nanoparticles using B16F10 melanoma cell lines. Int Nano Lett. 2013;36:3–9.10.1186/2228-5326-3-36 ↗